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SUMMARY 
The binding of bilirubin to poly(L-lysine) produces an optically active complex 
at pH 10.1. Circular dichroism spectra of these complexes are distinguishable from 
those generated by binding of bilirubin to the high affinity sites on albumin. Com- 
parison of the circular dichroism spectra of  bilirubin bound to the hepatic protein 
ligandin with those of bilirubin complexed with albumin or polylysine indicates that 
binding of bilirubin to ligandin occurs at two types of sites. These are distinguishable 
on the basis of their spectral properties, one resembling the high affinity site of bovine 
serum albumin and the other resembling polylysine. Complexes of biliverdin with 
albumin and ligandin bear similarities to the bilirubin-protein complexes. The native 
protein itself has an ordered structure which consists of 41 ~ a-helix and is not al- 
tered by the binding of bilirubin. 
INTRODUCTION 
Studies of the interaction of unconjugated bilirubin with serum albumin have 
shown that binding of the chromophore to protein generates an intense, biphasic 
circular dichroismi spectrum in the region of  the visible bilirubin absorption bands 
[1-5]. The high molar ellipticity values observed (>10  s deg.cmZ/dmol) have been 
attributed to fixation of the bilirubin molecule at the protein binding site in a con- 
figuration which is helical and inherently dyssymmetric. More recently, the name 
ligandin has been applied to a protein of the liver cytosol that binds bilirubin and other 
anions [6]° The identity of this protein with azo-dye carcinogen binding protein and 
corticosteroid I binding protein [7] and with glutathione S-transferase B [8] has been 
established. Circular dichroism data for the interaction of bilirubin with ligandin have 
been reported [9, 10]. Among the findings was the observation that the bilirubin- 
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ligandin CD spectrum differs qualitatively from that of bilirubin-albumin by the pres- 
ence of a band in the 500-580 nm region. This band increases in intensity after the ad- 
dition of more than 1 mol of bilirubin per mol of protein. Its origin has not been 
explained. 
We have investigated the optical properties of bilirubin bound to various model 
compounds such as synthetic amino acid polymers, as well as to proteins such as 
albumin and ligandin. The present study describes spectral data for the binding of 
bilirubin to the synthetic polymers poly(L-lysine) and poly(L-arginine) and to ligandin. 
The results indicate that the binding of the chromophore to polylysine generates a 
circular dichroism spectrum which is distinguishable from that produced by binding 
to the high affinity site of bovine serum albumin. Comparison with the ligandin case 
indicates that the CD spectrum of the bilirubin-ligandin complex consists of contri- 
butions from bilirubin bound at two types of sites. One of these resembles bilirubin- 
bovine serum albumin and one resembles bilirubin-polylysine in optical properties. 
MATERIALS AND METHODS 
Bilirubin (e~ra. 450 nm : 62 in chloroform) and biliverdin (emr~. 375 n r n  : 25 in 
methanol) were obtained from Sigma Chemical Corp. Poly(L-lysine) (Mr = 30 800) 
and poly(L-arginine) (Mr = 13 900) were obtained from Miles Laboratories. 
Rat ligandin was prepared by ion exchange chromatography and G75 Sepha- 
dex chromatography of rat liver supernatant [6] and stored frozen in 0.01 M Tris, 
pH 8.1. Purity was established by gel electrophoresis and by precipitation with mono- 
specific antibody. A molecular weight of 40 000 was assumed for the protein. Bovine 
and human serum albumin were the same preparations as previously described [2]. 
Spectral measurements were carried out in 0.1 M sodium phosphate buffer and 
all solutions were protected from light. Solutions of bilirubin and biliverdin were 
made up by first dissolving the pigments in small quantities of 0.1 M NaOH and then 
diluting with buffer. Absorption measurements were carried out on a Cary 15 re- 
cording spectrophotometer and circular dichroism measurements on a Jasco UV-5 
recording spectropolarimeter equipped with a Sproul Scientific SS-20 CD attachment. 
Circular dichroism results for the native protein are expressed in terms of [0], 
the mean residue ellipticity, using the value of n = 355 for the number of amino acid 
residues in the protein. The a-helix content of the native protein was calculated using 
the approximation of Greenfield and Fasman [11]. 
RESULTS 
Absorption spectra of bilirubin-polymer complexes 
Fig. 1 shows the absorption spectra of bilirubin bound to poly(L-lysine) and 
poly(L-arginine). In each case the effect of binding is to produce hypochromism in the 
bilirubin absorption with broadening of the spectrum on the long wavelength side. 
The composite nature of each spectrum is evident. The bilirubin-polylysine complex 
shows a maximum at 408 nm and broad shoulder in the 480 nm region, while the 
bilirubin-polyarginine complex shows a maximum at 420 nm and a broad shoulder 
in the 480 nm region. There is a distinct effect of pH on the absorption spectrum of 
bilirubin-polylysine. Full titration of the polymer to the uncharged state at pH 12 
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Fig. 1. Absorption spectra of bilirubin-amino acid polymer complexes. The absorption spectrum of 
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Fig. 2. Circular dichroism spectra of bilirubin-polylysine, pH 10.l at molar ratios of bilirubin to 
polymer of 2.0 and 4.0 tool/tool. 
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results in reversion of the bilirubin absorption spectrum to that of free bilirubin at 
the same pH. The spectrum at pH 10.1 is intermediate between the bound and free 
forms. 
CD spectra of bilirubin-polylysine and bilirubin-polyarginine 
Bilirubin-polylysine complexes are not optically active at pH 7.4 and at this 
pH the CD spectrum in the ultraviolet shows no formation of a-helix by the polymer. 
At pH 10.1 there is a-helical structure to the polymer, as judged by the CD spectrum 
in the far ultraviolet, and the bilirubin absorption bands become optically active with 
the appearance of a positive band at 525 nm and a negative band at 444 nm (Fig. 2). 
Loss of charge on the polymer at pH 12 results in loss of optical activity despite the 
persistence of a-helical structure. This correlates with the absorption spectrum at 
this pH, which is that of free bilirubin. Thus bilirubin-polylysine complexes show 
optical activity at pH 10.1, where the polylysine exists as a partially charged a-helix. 
Optical activity was best demonstrated at a bilirubin/polymer ratio of 4.0-8.0 mol/ 
mol, based on the molecular weight of 30 800 for the entire polymer. However, 
optical activity was clearly demonstrable at a bilirubin/polymer ratio of 0.7, indicating 
that bilirubin-bilirubin stacking interactions are not essential to the generation of op- 
tical activity. 
Bilirubin-polyarginine complexes were not optically active in this pH range, 
as the polymers did not form a-helical structures between pH 7 and pH 12. 
CD spectra of bilirubin-ligandin complexes 
The CD spectra at various molar ratios of bilirubin to ligandin are shown in 
Fig. 3. At bilirubin/protein ratios of 1.0 or less, the spectrum is very similar to that 
of bilirubin-bovine serum albumin. Above 1 mol bilirubin/mol protein a new band 
appears with a maximum at 515 nm and in the region of 1-4 tool of bilirubin/mol 
protein the changes in the spectrum are dominated by the increases in the size of this 
band. The maximum intensities at 408 nm and 465 nm are almost achieved by the ad- 
dition of one mole of bilirubin per mol of protein, while the band at 515 nm continues 
to increase up to 4 tool bilirubin/mol protein. 
Certain other features of these CD spectra are of importance. Accompanying 
the increase in ellipticity at 515 nm, there is a small increase in the magnitude of the 
large negative band, which is also shifted 10 nm from 465 nm to 455 nm. At the same 
time, the band at 405 nm decreases in magnitude. These latter changes could be ac- 
counted for by the presence of another negative band between 405 nm and 465 nm 
which increases in magnitude simultaneously with the positive band at 515 nm. In 
this respect, the results of a computer analysis of the bilirubin-ligandin CD spectrum 
are of interest. A curve-fitting program (Modelaide) written by Richard I. Shrager of 
the NIH Division of Computer Resources and Technology was utilized to assign the 
best fit of  Gaussian curves to the spectrum. Although the assumption of three Gaus- 
sian components provided good fit to the data, an improved fit was obtained by al- 
lowing for the presence of a fourth band, negative in sign, and positioned at 437 nm 
(Fig. 4). 
The CD spectrum of native ligandin was in agreement with that previously 
reported [9, I0]. In the far ultraviolet the calculated mean residue ellipticity per pep- 
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Fig. 3. Circular dichroism spectra of bilirubin-ligandin, pH 7.4, at molar ratios of bilirubin to protein 
of 1.0, 2.0, and 4.0 mol/mol. For comparison, the CD spectra of 1:1 complexes of bilirubin-bovine 
serum albumin and bilirubin-human serum albumin are also shown. 
protein was estimated at 41%. This agrees well with other independent measurements 
o f  this value [9, 10]. The binding of  bilirubin to the protein did not  alter this content  
o f  a-helix. In the near ultraviolet the spectrum is complex, indicating the presence o f  
several oriented chromophores .  The salient features are a negative band at 296 nm, 
positive bands at 291 nm and 284 nm and negative bands at 268 nm and 261 nm. A 
broad shoulder between 270 nm and 280 nm contains at least one additional positive 
band. U p o n  binding of  bilirubin, a new positive band appears at 252 nm. Although 
an oriented disulphide bond could produce a transition in this spectral region, it is 
more likely that  this represents the shoulder o f  an optically active bilirubin absorption 
band at 220 nm. 
Absorption and CD spectra of biliverdin binding to protein 
The binding of  biliverdin to albumin and to ligandin was investigated. The 
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Fig. 4. Computer-fitted representation of the biIirubin-ligandin CD spectrum as the sum of three 
and of four Gaussian components. I ,  experimental points; ~, fitted points. 
Unlike the bilirubin absorption spectrum which shows strong dependence upon 
solvent, the biliverdin spectrum was rather insensitive to solvent changes. The peak 
at 374 nm in aqueous solution was shifted to 379 nm in chloroform with no change in 
extinction. Binding to protein also produced slight shifts in the 374 nm peak, to 379 
nm upon binding to human serum albumin and to 383 nm for binding to ligandin, 
without change in extinction. The long wavelength band at 640 nm showed little or 
no change in position or intensity as the result of  binding to protein. 
Circular dichroism spectra for the binding to human serum albumin and li- 
gandin are shown in figure 5. Optical activity of both visible bands occurs, the two CD 
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Fig. 5. CD spectra of biliverdin-human serum albumin and biliverdin-ligandin. Inset shows absorp- 
tion spectrum of free biliverdin. 
biliverdinobovine serum albumin and biliverdin-ligandin were of the same chirality 
and were opposite to that of the biliverdin-human serum albumin complex. Spectrally 
distinct binding sites were not observed. Biliverdin was able to displace bilirubin from 
its high affinity site on ligandin, in that a 10 molar excess of biliverdin reduced the in- 
tensity of the 460 nm CD band of a 1:1 bilirubin-ligandin complex by about 65 ~o. 
D I S C U S S I O N  
Circular dichroism data for bilirubin-protein complexes have been reported by 
numerous authors [1-5, 9, 10, 13]. Binding of bilirubin to the first high affinity site 
on albumin produces a spectrum that consists of two intense ellipticity bands of op- 
posite sign with maxima located in the 405-415 nm region and the 455-470 nm region. 
Although marked changes in these spectra may accompany changes in pH [3], salt 
concentration [4], or molar ratio of bilirubin to protein [2, 4], or the addition of com- 
peting anions [2], the occurrence of a distinct CD band beyond 500 nm is not ob- 
served. The interaction of one mole of bilirubin with ligandin produces a CD spectrum 
that is qualitatively similar to that of a 1:1 complex of bilirubin-bovine serum albumin. 
However, further increase of the molar ratio of bilirubin to ligandin produces increas- 
ed ellipticity in the 500--580 nm region and slight blue shift of the 465 nm band. These 
phenomena indicate that the long wavelength band results from the binding of bili- 
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rubin to additional sites (s) that are of lower affinity than the first and are also of dif- 
ferent spectral properties. The finding that optically active complexes of bilirubin- 
polylysine at pH 10 exhibit ellipticity in the 500-580 nm region provides an explana- 
tion for the behavior of the bilirubin-ligandin complexes. Such an interpretation would 
require the presence of a second negative band in the bilirubin-ligandin spectrum, and 
the behavior of this spectrum is consistent with the existence of such a band. Further- 
more, computer resolution of the spectrum yields an improved fit to the data when a 
negative band at 437 nm is included. While such a computer resolution does not con- 
stitute proof of the existence of a band, the results are consistent with that interpre- 
tation. 
Bilirubin-polyarginine complexes were not optically active, but their absorp- 
tion spectra were quite like those of bilirubin-polylysine. It thus seems probable that 
binding of bilirubin to either arginine or lysine residues within the oriented structure 
of a protein could give rise to CD spectra of the same general character as those of 
bilirubin-polylysine. 
It is thus possible to distinguish two types of protein binding sites for bilirubin 
on the basis of circular dichroism properties. Kuenzle [12] has presented evidence that 
free bilirubin in solution exists in the form of an internally stabilized resonance 
hybrid in which the propionic acid carboxyl groups are hydrogen-bonded to the pyr- 
role nitrogens and to the pyrrolenone oxygen atoms on the outer rings. The disruption 
of this structure upon binding to polylysine may be in part responsible for the observed 
spectral changes. In addition, the absorption spectrum of bilirubin is rather strongly 
dependent upon solvent and the distinction between the two sites of binding to li- 
gandin may be also due to differences in the hydrophobic character of the first site 
relative to the second. 
The CD data for biliverdin-ligandin complexes provide useful comparison 
with the bilirubin case. Previous descriptions [14-16] have indicated that both bovine 
and human serum albumin complexes of biliverdin are optically active. The con- 
figurations of these spectra show rather marked dependence upon pH and upon the 
specific binding protein. Blauer [16] has reaffirmed the importance of a highly specific 
mode of binding between pigment and protein with respect to the generation of cir- 
cular dichroism spectra, and has indicated that the geometry of the bilirubin and bili- 
verdin molecules may be correlated with the observed spectral data. Our data for the 
biliverdin-human serum albumin complex at pH 7.4 were in agreement with those 
described by Blauer [14, 16]. The data for the biliverdin-ligandin complexes showed 
the occurrence of well defined CD bands which were of opposite chirality to the bili- 
verdin-human serum albumin complexes. Spectra of biliverdin-bovine serum albumin 
complexes at pH 7.4 showed that under these circumstances, the chirality was the 
same as that of biliverdin-ligandin. This appears to agree with the observations of Lee 
and Cowger [15] for biliverdin-bovine serum albumin at this pH. Thus for both bili- 
rubin and biliverdin, the complexes with ligandin and bovine serum albumin are of life 
chirality and are opposite to those of the human serum albumin complexes. This indi- 
cates the role of these proteins in fixing the two chromophores into specific twisted 
conformations. 
These data provide further indications of the utility of circular dichroism as a 
tool for the study of the interactions of bile pigments with protein. Such consider- 
ations may be applicable to other systems such as the basic myelin protein of Gurba 
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and Zand  [13] which binds bi l i rubin  and upon  do ing  so exhibits  C D  in the 500-600 
nm region. I t  is also possible  to cons ider  the theoret ical  s i tua t ion  o f  a C D  spectrum 
derived f rom one pro te in  b ind ing  site o f  the b i l i rub in-human serum a lbumin  chira l i ty  
plus an add i t iona l  site of  the  b i l i rubin-poly lys ine  character .  Such a combina t ion  does 
not  appea r  to  have been observed in pract ice  but  may  be encountered  with fur ther  
studies. 
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